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Abstract 
Background: The beneficial outcome associated with the use of proton pump inhibitors (PPIs) in idiopathic pulmo‑
nary fibrosis (IPF) has been reported in retrospective studies. To date, no prospective study has been conducted to 
confirm these outcomes. In addition, the potential mechanism by which PPIs improve measures of lung function and/
or transplant‑free survival in IPF has not been elucidated.
Methods: Here, we used biochemical, cell biological and preclinical studies to evaluate regulation of markers 
associated with inflammation and fibrosis. In our in vitro studies, we exposed primary lung fibroblasts, epithelial and 
endothelial cells to ionizing radiation or bleomycin; stimuli typically used to induce inflammation and fibrosis. In addi‑
tion, we cultured lung fibroblasts from IPF patients and studied the effect of esomeprazole on collagen release. Our 
preclinical study tested efficacy of esomeprazole in a rat model of bleomycin‑induced lung injury. Furthermore, we 
performed retrospective analysis of interstitial lung disease (ILD) databases to examine the effect of PPIs on trans‑
plant‑free survival.
Results: The cell culture studies revealed that esomeprazole controls inflammation by suppressing the expression 
of pro‑inflammatory molecules including vascular cell adhesion molecule‑1, inducible nitric oxide synthase, tumor 
necrosis factor‑alpha (TNF‑α) and interleukins (IL‑1β and IL‑6). The antioxidant effect is associated with strong induc‑
tion of the stress‑inducible cytoprotective protein heme oxygenase‑1 (HO1) and the antifibrotic effect is associated 
with potent inhibition of fibroblast proliferation as well as downregulation of profibrotic proteins including receptors 
for transforming growth factor β (TGFβ), fibronectin and matrix metalloproteinases (MMPs). Furthermore, esomepra‑
zole showed robust effect in mitigating the inflammatory and fibrotic responses in a murine model of acute lung 
injury. Finally, retrospective analysis of two ILD databases was performed to assess the effect of PPIs on transplant‑free 
survival in IPF patients. Intriguingly, this data demonstrated that IPF patients on PPIs had prolonged survival over 
controls (median survival of 3.4 vs 2 years).
Conclusions: Overall, these data indicate the possibility that PPIs may have protective function in IPF by directly 
modulating the disease process and suggest that they may have other clinical utility in the treatment of extra‑intesti‑
nal diseases characterized by inflammatory and/or fibrotic phases.
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Background
Idiopathic pulmonary fibrosis (IPF) is a fibrosing lung 
disease of unknown etiology that causes progressive loss 
of lung function. It has an incidence of 93.7 cases per 
100,000 and prevalence of 494.5 cases per 100,000 [1]. 
Most patients are over 60  years old, but patients with 
familial IPF may present earlier [2–4]. IPF has a median 
survival of only 3–4  years from the time of diagnosis 
[1]. Recently FDA approved drugs, pirfenidone and nin-
tedanib, only slow the disease progression [5, 6] and 
development of more effective therapies are hampered by 
an incomplete understanding of the factors involved in 
the disease pathogenesis.
Recently, a number of retrospective or prospective 
case series studies that reviewed interstitial lung disease 
databases have reported that IPF patients placed on anti-
acid therapy (mainly on proton pump inhibitors; PPIs, 
in comparison to Histamine H2-inhibitors; H2Is) appear 
to have improved outcomes in measures of lung func-
tion and overall health including longer period of lung 
transplant-free survival, reduced hospitalization for pul-
monary-related illnesses and significantly reduced epi-
sodes of acute exacerbations [7–9]. However, given the 
high prevalence of gastric reflux in IPF patients [10], it is 
unclear whether the presumed beneficial effect of PPIs is 
due primarily to the action of reducing gastric acidity and 
consequently suppressing apparent microaspiration to 
pulmonary parenchyma or due to potential regulation of 
other biological processes involved in IPF pathogenesis.
PPIs are a class of drug that share a benzimidazole 
compound as a common core structure and are known to 
possess other biological activities apart from suppression 
of proton pumps which are mainly expressed by acid-
secreting parietal cells of the stomach [11]. In vitro and 
in vivo studies have shown that PPIs have antioxidant and 
anti-inflammatory functions in various cell types includ-
ing immune, vascular endothelial and epithelial cells [12, 
13]. The antioxidant property of the PPIs is reported to 
be due to direct scavenging of reactive oxygen species 
(ROS) and induction of the stress-inducible protein heme 
oxygenase-1 (HO1) [12, 14]. Meanwhile, the effect on 
inflammation was attributed to regulation of neutrophil 
chemotaxis and phagocytosis [15, 16], attenuation of free 
radical production by immune cells [17–19] and down-
regulation of pro-inflammatory/profibrotic cytokines [13, 
20] as well as inhibition of interaction between inflam-
matory and vascular cells [21] (Fig. 1).
Recently, we reported [22] that the PPIs regulate the 
nitric oxide (NO) synthase (NOS) pathway by inhibit-
ing dimethylarginine dimethylaminohydrolase (DDAH); 
an enzyme that is ubiquitously expressed in various seg-
ments of the lungs including the endothelium, bronchi 
and alveoli, in one of two isoforms [23]. In IPF, it has 
been reported that the NOS/DDAH pathway is upregu-
lated [24]. Moreover, IPF patients show increased mark-
ers of nitrosative stress, including significantly higher 
levels of plasma nitrite [24, 25]. Genetic manipulation 
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Fig. 1 Overview of pleiotropic effect of proton pump inhibitors (PPIs). The PPIs modulate inflammation, oxidative stress, fibrosis, cell proliferation 
and survival by regulating signaling pathways that are involved in these processes.
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lung injury with inhibitors of NOS or DDAH improve 
lung compliance [24, 26].
Overall, simultaneous regulation of inflammation as 
well as oxidative and nitrosative stress by the PPIs led 
us to develop the following hypotheses: (1) PPIs reduce 
the production of pro-inflammatory cytokines by lung 
epithelial and vascular endothelial cells exposed to 
inflammatory stimuli; (2) PPIs regulate markers of fibro-
sis including the production of soluble collagen by lung 
fibroblasts isolated from IPF patients; (3) PPIs attenuate 
inflammation and fibrosis in an animal model of acute 
lung injury; and (4) IPF patients receiving PPIs would 
have better clinical outcomes compared to IPF patients 
not receiving PPIs.
Accordingly, we conducted in vitro and in vivo experi-
ments to evaluate the ability of a prototype PPI, esome-
prazole, in regulating markers of inflammation, apoptosis, 
oxidative stress and fibrosis in primary lung cell types 
including fibroblasts, epithelial as well as endothelial 
cells. In vivo, we assessed the efficacy of esomeprazole 
in attenuating lung inflammation and fibrosis in a rat 
model of bleomycin-induced lung injury. Clinically, we 
performed retrospective study to assess if there is a cor-
relation between PPI use and prolonged lung transplant-
free survival in IPF patients including these who have had 
no symptoms of gastric reflux; a condition for which the 
PPIs are mainly prescribed.
Methods
Cell proliferation assay
Lung fibroblasts were isolated under consent from IPF 
patients undergoing transplantation as we described pre-
viously [27]. Characterization of the cells is described in 
the Additional file  1 of this manuscript. For the prolif-
eration assay, 3 × 103 cells/well were seeded in a 96-well 
plate and incubated overnight at 37°C/5%CO2. The next 
day, the cells were synchronized by serum starvation 
for 2  h followed by 22  h low serum (0.1% fetal bovine 
serum, FBS) treatment. On day 3, the cells were stimu-
lated with 10% FBS containing media in the presence of 
esomeprazole or vehicle and were further cultured under 
this condition for 24 h. Furthermore, the cells were incu-
bated with 5-bromo-2-deoxyuridine (BrdU; 20  µL of 
1:500 dilution) for 24 h to assess the effect of esomepra-
zole on proliferation. Finally, the incorporation of BrdU 
into newly synthesized DNA of proliferating cells was 
detected immunochemically using an antibody directed 
against BrdU using a BrdU Cell Proliferation Assay kit 
(Millipore). Similarly, the effect of esomeprazole on the 
proliferation of primary lung epithelial cells (Lonza) was 
assessed.
Exposure of primary lung cells to bleomycin
IPF lung-derived or normal lung fibroblasts as well as 
normal primary lung epithelial and endothelial cells 
(Lonza) were cultured and expanded using standard cell 
culture techniques. In this study, the cells were treated 
with esomeprazole or vehicle for 24 h in the presence or 
absence of bleomycin (Sigma; at 25 µg/mL final concen-
tration). Subsequently, the cells were harvested and total 
RNA was extracted using the PerfectPure RNA Cell and 
Tissue kit (5 PRIME). Next, the concentration and qual-
ity of the RNA were validated using a Nanodrop (Tecan) 
and 2 µg of RNA was reverse transcribed using the High 
Capacity RNA-to-cDNA Kit (Applied Biosystems). The 
resulting cDNA was used for gene expression study by 
quantitative RT-PCR. Quantitative RT-PCR (qRT-PCR) 
was performed using standard TaqMan gene expression 
assay using proprietary “best coverage” primer/probe 
sets (Life Technologies) as described below.
Exposure of primary lung epithelial cells to ionizing 
radiation in a 3D culture system
For ionizing radiation experiments, primary lung epi-
thelial cells were cultured in a three-dimensional (3D) 
culture system. In brief, standard T75 flasks were coated 
with MaxGel (Sigma) extracellular matrix (ECM; a 
human basement membrane extract which provides 
tissue-like microenvironment due to its composition of 
collagen, fibronectin, laminin, elastin and other proteo-
glycans) for 4  h at 37°C/5%CO2. The solution was aspi-
rated prior to allowing the flasks to air-dry for 30 min at 
room temperature. Subsequently, primary human bron-
chial epithelial cells (Lonza) were suspended in epithelial 
cell growth media (BEGM) and seeded in the pre-coated 
3D flasks. When the cells reached 60% confluency, they 
were treated with esomeprazole or vehicle for 24 h prior 
to irradiation. The cells were X-ray irradiated by expo-
sure to 6 Gray (6  Gy) of continuous ionizing radiation 
(RS-2000 Biological System; Rad Source Technologies) 
applied at a rate of 2  Gy/min. Subsequently, the irradi-
ated and control cells were incubated at 37°C/5%CO2 for 
additional 6 h prior to harvesting and RNA extraction as 
described above.
Gene expression study
For gene expression study, cDNA was generated as 
described above and was used for real-time RT-PCR 
to compare the effect of esomeprazole on the mRNA 
expression of HO1, tumor necrosis factor alpha (TNF-
α), interleukins (IL-1β and IL-6), p53, adhesion mol-
ecules (VCAM-1 and ICAM-1), TGFβ and its receptors 
(TGFβR1 and TGFβR2), matrix metalloproteinases 
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(MMPs), collagen type 1 (COL1A1), fibronectin 1 (FN1), 
Chitinase 3-like 1 (CHI3L1) and inducible NOS (iNOS). 
A QuantStudio 12  K Flex Real-Time PCR System (Life 
Technologies) was used for the analyses. Each reaction 
contained 10  µL of TaqMan Universal PCR Master mix 
(2X), 1 µL of TaqMan assay containing primers and MGB 
probe mix (20X) and 3 µL of cDNA in 20 µL final volume. 
The reaction was carried out in a 96-well plate under the 
following condition: incubation at 50°C for 2 min; dena-
turation at 95°C for 10 min followed by 95°C for 15 s and 
finally annealing and extension at 60°C for 2 min for 34 
cycles in total. The data was analyzed using the Quant-
Studio gene expression software and fold changes in 
mRNA expression were calculated by standardizing to 
β-actin internal control.
In vivo study of bleomycin‑induced lung inflammation 
and fibrosis
We conducted a 28-day study using male Fischer rats 
(F344 strain) to assess the efficacy of esomeprazole in 
inhibiting or attenuating the progression of bleomycin 
sulfate-induced lung fibrosis using an intra-tracheal (IT) 
instillation model. The study was conducted at Lovelace 
Respiratory Research Institute (LRRI) and the experimen-
tal design (shown in Table 1) consisted of 6 randomized 
groups receiving bleomycin sulfate (BS) and 1 group 
receiving saline by intra-tracheal instillation on study 
day 0. In brief, the animals were anesthetized using 4–5% 
isoflurane in oxygen until a deep plane of anesthesia was 
achieved. Next, normal saline or BS dissolved in normal 
saline (250–340 µL based on body weight) was adminis-
tered to each animal according to their grouping. Follow-
ing instillation and brief recovery, animals that received 
normal saline (Group 1) received vehicle (10% ethanol) 
once daily (QD) by oral gavage (PO) on days 10–28. BS 
control animals (Group 2) received vehicle (QD, PO) on 
days 10–28. Groups 3–6 received esomeprazole at 30 or 
300  mg/kg (QD, PO prepared in 10% ethanol) on Days 
2–28 (prophylactic model) or 10–28 (therapeutic model). 
Group 7 received the control drug pirfenidone [28] at 
100 mg/kg by PO, twice daily (BID) on days 10–28. Dur-
ing the course of the study, blood samples were collected 
for biochemical and pharmacokinetic study as described 
below. On day 28, shortly after the final drug dose, the 
animals were euthanized using pentobarbital solution. 
At necropsy, terminal blood samples were collected by 
cardiac puncture, processed to plasma, and stored fro-
zen for bioanalytical and biochemical studies. In addi-
tion, bronchoalveolar lavage (BAL) was performed and 
BAL fluid (BALF) collected for soluble collagen analysis 
as described below. Furthermore, the left lung lobes were 
fixed for DNA fragmentation (TUNEL) assay and for his-
tological analyses including H&E and Sirius Red collagen 
staining as described below. The right caudal lung lobes 
were used for hydroxyproline assay as described below 
and the right lung lobes were individually flash frozen 
and subsequently used for microarray study as described 
below.
Pharmacokinetics of esomeprazole
Five animals each from the low-dose and high-dose of 
prophylactic esomeprazole were used to determine the 
concentration of esomeprazole in plasma and lung tis-
sue. In brief, blood was collected prior to dosing on day 
0, 1 h after dosing on day 15, 1 h after dosing on day 20, 
and again at sacrifice (day 28). Meanwhile, pharmacoki-
netic (PK) study was carried out on day 5 by collecting 
blood at 0.5, 1, 2, and 3 h post dosing. Esomeprazole in 
plasma was extracted using a protein precipitation pro-
cedure. Briefly, the plasma was thawed from storage at 
−80°C and aliquoted in 100 µL. To this, 50 µL of acetoni-
trile or spiking solutions in acetonitrile were first added 
followed by the addition of 300  µL of acetonitrile con-
taining 10  ng/mL of omeprazole-d3 (internal standard). 
The samples were mixed for 10 s and then centrifuged at 
13,000 rpm for 5 min. The supernatant was transferred to 
Table 1 Experimental design of bleomycin sulfate (BS)-induced lung fibrosis in a 28-day rat model
Initially, the groups were exposed to normal saline or BS intra-tracheally (IT) and then received vehicle, esomeprazole (prophylactically or therapeutically) or 
therapeutic pirfenidone orally (PO) for the indicated course.
N number of animals, BID twice daily, Eso esomeprazole.
Group ID Exposure N Bleomycin dose  
(mg/kg), Route
Eso dose  
(mg/kg)
Route Dosing  
days
Necropsy day
1 Saline‑vehicle control 6 0, IT Vehicle PO 10–28 28
2 BS control 10 ~4.0, IT Vehicle PO 10–28 28
3 BS + eso low therapeutic 10 ~4.0, IT 30 PO 10–28 28
4 BS + eso high therapeutic 10 ~4.0, IT 300 PO 10–28 28
5 BS + eso low prophylactic 15 ~4.0, IT 30 PO 2–28 28
6 BS + eso high prophylactic 15 ~4.0, IT 300 PO 2–28 28
7 BS + pirfenidone 10 ~4.0, IT 100 PO, BID 10–28 28
Page 5 of 20Ghebremariam et al. J Transl Med  (2015) 13:249 
labeled autosampler vials with inserts, and the drug con-
centration was analyzed by liquid chromatography-mass 
spectrometry (LC–MS) methods developed at Lovelace 
Respiratory Research Institute (LRRI) and based on pub-
lished protocol [29]. Concentration versus time values in 
plasma samples were used to determine PK parameters 
of esomeprazole including half-life (T1/2), peak concen-
tration (Cmax), time to peak concentration (Tmax) and 
area under the concentration/time curve (AUC). Simi-
larly, esomeprazole in lung tissue was extracted using a 
protein precipitation procedure. Briefly, the lungs were 
thawed from storage at −80°C and 100  mg each was 
homogenized in 1 mL of Dulbecco’s phosphate buffered 
saline (PBS). From the homogenate, 100 µL of superna-
tant was aliquoted and processed for determination of 
tissue esomeprazole concentration as described for the 
plasma samples above.
Soluble collagen and hydroxyproline assays
For the quantification of soluble collagen in BALF, the 
right lungs were lavaged twice with 3  mL of PBS. The 
lavagates were pooled together for each group and 
200 µL of supernatant each was assayed for soluble col-
lagen by colorimetric Sircol assay following the manufac-
turer’s (BioColor) recommended protocol. Similarly, the 
right caudal lung lobe was homogenized and analyzed 
for tissue hydroxyproline content by colorimetric assay. 
Finally, the amount of collagen in the BALF and lung tis-
sue samples was estimated from standard curve and was 
expressed as µg collagen per 200 µL BALF and µg colla-
gen per lung lobe respectively.
ELISA assays
The concentration of IL-1β, MMP7, CHI3L1, bilirubin, 
ADMA and NO in rat plasma was determined using 
respective ELISA-based biochemical assays as per the 
recommendations of the respective commercial purvey-
ors. Respective standard curves were used to estimate the 
concentration of each of the analytes and the Mean val-
ues were used for comparison among the groups.
Histopathology and immunofluorescence study
For this study, left lung lobes were fixed in 10% neutral 
buffered formalin (NBF) and then processed to slides 
for immunohistochemistry. In brief, the tissues were 
trimmed beginning at a random start point approxi-
mately 3–5  mm from the cranial end of the lobe. Fixed 
lungs were cut transversely each 3–4 mm and every sec-
tioned tissue was submitted for histology. Tissues were 
paraffin embedded and sectioned at approximately 4 µm 
thickness to produce two serial sections for histopatho-
logical analyses. One section was stained with Hema-
toxylin and Eosin (H&E) in order to assess inflammation 
and overall tissue architecture and the other was stained 
with Sirius Red (SR) to examine collagen deposition and 
fibrotic changes. H&E slides and corresponding SR slides 
were microscopically examined together and graded sub-
jectively according to their degree of inflammation and 
fibrosis respectively. In brief, a pathologist graded the 
lesions in a semi-quantitative fashion on a scale of 1–4 
(1 = minimal, 2 = mild, 3 = moderate, 4 = severe).
For the immunohistochemical staining of rat lung tis-
sue for alpha-smooth muscle actin (α-SMA; Sigma) and 
Collagen 1 (Col1A1; Sigma), we used standard stain-
ing protocol. In brief, paraffin embedded sections were 
mounted into slides (5 µm thickness) and incubated over-
night in a 60°C oven. Next, the slides were allowed to cool 
prior to deparaffinization and rehydration. Subsequently, 
the antigen was retrieved by boiling the slides in 10 mM 
sodium citrate solution (pH 6.0) and non-specificity 
was blocked with 2.5% horse serum for 30 min at room 
temperature (RT). Subsequently, the slides were incu-
bated with their respective primary antibodies: α-SMA 
(1:2,000), Col1A1 (1:2,000) for 1  h at RT. The next day, 
the antibodies were washed off and the slides were incu-
bated with biotinylated secondary antibodies for 30 min 
at RT in moist chamber. Finally, the slides were incubated 
in streptavidin-HRP solution for 30 min prior to adding 
DAB substrate, counterstaining with Hematoxylin and 
mounting. Multiple non-overlapping microscopic fields 
were scanned and reviewed by a pathologist in a blinded 
fashion.
TUNEL assay
The left lung lobe was processed to slides, stained for 
fragmented DNA (TUNEL assay) and analyzed at LRRI’s 
Pulmonary Fibrosis Laboratory to determine the ratio of 
apoptotic cells. In addition, double immunofluorescence 
staining was performed for the pro-apoptotic protein p53 
(Invitrogen) and the epithelial cell marker prosurfactant 
protein C (proSP-C; Millipore) in order to delineate the 
degree of apoptosis in the epithelial cells subpopulation. 
In brief, slide-mounted lung sections were simultane-
ously stained with both primary antibodies (1:200 diluted 
mouse anti-p53 and 1:800 diluted rabbit anti-proSP-C) 
and then with their respective secondary antibodies con-
jugated to different fluorophores for differential analysis. 
The slides were mounted in a mounting media contain-
ing DAPI (nuclear stain) and examined for colocalization 
of the two proteins to mark the degree of epithelial cell 
death.
Lung tissue microarray study
For this study, total RNA was extracted from lung 
tissue homogenates using the isolation technique 
described above. The quality of the RNA including the 
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concentration and integrity was checked using a bioana-
lyzer 2100 (Agilent Technologies) at the Baylor College 
of Medicine, Genomic and RNA Profiling Core. Subse-
quently, RNA samples were subjected to GeneChip Rat 
Exon ST 1.0 Array for comprehensive analysis of the rat 
lung genome. In brief, the RNA (100  ng each) was first 
converted to first-strand cDNA and then to second-
strand prior to overnight amplification of the cRNA. 
The next day, the cRNA (15  µg) was purified and used 
for single-strand cDNA (ss-cDNA) synthesis. Next, the 
template RNA was removed and the ss-cDNA (5.5  µg) 
was purified prior to being fragmented and biotin conju-
gated for hybridization. Subsequently, 200 µL hybridiza-
tion cocktail containing Affymetrix spike-in controls and 
the conjugated cDNA was loaded onto a GeneChip® Rat 
Exon 1.0 ST array. The arrays were hybridized for 17 h at 
45°C, with rotation at 60 rpm on a GeneChip® Hybridiza-
tion Oven 640. The arrays were then washed and stained 
with a Streptavidin, R-phycoerythrin conjugate on a 
GeneChip® Fluidics Station 450. Signal amplification was 
assessed using biotinylated antistreptavidin. The stained 
arrays were scanned on an Affymetrix GeneChip® Scan-
ner 3000. The images were analyzed and quality control 
metrics recorded using Affymetrix Command Console 
software version 4.0.0. Finally, the transcript expression 
data was clustered into signaling pathways and presented 
in heatmap format for comparison.
IPF patient population, demographics and clinical data
Two hundred fifteen (215) patients from the Stanford 
University and the University of Alabama at Birming-
ham (UAB) ILD databases, diagnosed with IPF according 
to evidence-based guidelines [30] were studied. Patients 
were analyzed in the PPI treatment group if they were on 
any PPI for at least 12 months. Survival time was defined 
as time to either death or lung transplantation. Patients 
were excluded if: (1) they were lost to follow-up before 
12 months; (2) pulmonary function tests (PFTs) were not 
available; (3) FEV1/FVC was ≤0.70; and (4) PPI therapy 
lasted less than 12  months for reasons other than lung 
transplantation or death.
Statistical analysis
For the in vitro cell culture studies, Mean value ± stand-
ard error mean (SEM) of each data is presented unless 
stated otherwise. Multiple groups were compared using 
one-way analysis of variance (ANOVA) followed by Bon-
ferroni posttest correction. Two groups were compared 
by student’s t test using GraphPad Prism 5 software (La 
Jolla, CA, USA).
For the in  vivo preclinical study, Means and stand-
ard deviations (SD) were calculated for collagen and 
hydroxyproline measurements. ANOVA was performed 
to evaluate the effect of bleomycin sulfate and esome-
prazole or pirfenidone treatment, to compare treatment 
groups for soluble collagen, hydroxyproline, and other 
endpoints. Where there was a significant treatment effect 
(p < 0.05), Dunnett’s multiple comparison was performed 
to assess differences between treated and control groups.
For the microarray study, a one-way ANOVA based 
on the method of Eisenhart [31] was used for treatment 
effect (prophylactic, therapeutic and vehicle). Fisher’s 
least significant difference was used with contrasts [32] 
for pairwise group comparisons: prophylactic vs. thera-
peutic, prophylactic vs. vehicle, and therapeutic vs. 
vehicle.
The clinical data for survival was analyzed using 
Kaplan–Meier. Data was presented as statistically signifi-
cant when the p value was less than 0.05 (p < 0.05). A Cox 
proportional hazard model was used to identify predic-
tors of survival time, i.e., time to transplant or death.
Study approval
The animal study was reviewed and approved by Lovelace 
Respiratory Research Institute (LRRI)’s vertebrate animal 
use research committee (IACUC approval # FY14-084).
The isolation of lung fibroblasts from IPF patients was 
performed under consent following review and approval 
by Stanford University’s Institutional Review Board (IRB) 
(approval # 18891).
All other reagents used in this study are from commer-
cial sources.
Results
Esomeprazole inhibits the proliferation of primary lung 
cells in vitro
Hyperplasia of alveolar epithelial (ATII) cells, although 
inconclusive, is reported to be pathologically involved 
in lung fibrosis through the process of epithelial-to-
mesenchymal transition (EMT) [33, 34]; by serving as 
precursor cells for fibroblast-driven fibrosis. In addi-
tion, over-proliferation of fibroblasts contributes to 
pathological deposition of extracellular matrix in the 
lungs [35]. In this study, we found that esomeprazole 
dose-dependently attenuated serum-induced prolifera-
tion of both lung fibroblasts (by about 50% at 50  µM; 
p  <  0.05) and epithelial cells (by over 90% at 50  µM; 
p < 0.05), as demonstrated by reduced BrdU incorpora-
tion into newly synthesized DNA (Fig. 2). These effects 
of esomeprazole occurred at doses that were not asso-
ciated with cytotoxicity. Specifically, we treated lung 
fibroblasts and epithelial cells with increasing concen-
tration of esomeprazole for 24 h and studied the release 
of lactate dehydrogenase (LDH) into the conditioned 
media. Treatment with esomeprazole at concentrations 
significantly higher than used in the proliferation assay 
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was not associated with cytotoxicity (Additional file  1: 
Figure S1).
Esomeprazole attenuates elaboration of inflammatory 
response to bleomycin and radiation in vitro
A typical cellular response to bleomycin or ionizing 
radiation is a burst in markers of inflammation [36, 37]. 
Interestingly, pre-incubation of primary lung epithe-
lial cells with esomeprazole prior to exposure to ion-
izing radiation significantly (by about 50%; p  <  0.05) 
suppressed the expression of pro-inflammatory mark-
ers including TNF-α, IL-6 and nuclear factor kappa B 
(NFκB) (Fig.  3a). Moreover, esomeprazole downregu-
lated the expression of p53 (Fig. 3b) and upregulated the 
anti-inflammatory molecule HO1 (Fig.  3c) (p  <  0.05 at 
50  µM). Furthermore, pre-incubation of lung epithelial 
cells, fibroblasts or endothelial cells with esomeprazole 
substantially inhibited bleomycin-induced inflammatory 
response, as well as markers of fibrotic response includ-
ing components of the TGFβ/MMP pathway (Fig. 4a–c). 
In addition, the expression of HO1 was increased in each 
of these lung cell types (Fig. 4d–f ) (p < 0.05 at 50 µM).
Esomeprazole inhibits TGF‑β‑induced collagen synthesis 
by lung fibroblasts isolated from IPF patients
Here, we investigated whether esomeprazole directly 
regulates soluble collagen production by lung fibroblasts. 
Primary fibroblasts were isolated from IPF patients as 
described and were characterized by positive staining 
for several myofibroblast markers (Additional file 1: Fig-
ure S2). Intriguingly, incubation of the cells with esome-
prazole attenuated TGF-β-stimulated collagen release 
(Fig. 5).
Esomeprazole suppresses lung inflammation and fibrosis 
in vivo
Subsequent to the robust anti-inflammatory and anti-
fibrotic property of esomeprazole demonstrated in vitro, 
we examined these properties in  vivo in an animal 
model characterized by inflammation and fibrosis (i.e. 
the bleomycin-induced acute lung injury model). Daily 
administration of esomeprazole starting 2  days after 
the induction of lung injury by bleomycin yielded dose 
dependent drug levels in the plasma and lung tissue 
(Additional file  1: Table S1) and resulted in robust sup-
pression of inflammation (Fig.  6) and fibrotic changes 
(Fig.  7) to the lungs including maintenance of normal 
lung tissue with no microscopically detectable lesions in 
35% of the animals in the low dose esomeprazole group 
and in 20% of the animals that received the high dose 
of esomeprazole. The overall inflammation and fibrosis 
score is shown as Table  2. In addition, stainings of the 
lung tissues for the smooth muscle cell marker alpha 
smooth muscle actin (α-SMA) and the extracellular 
matrix component Collagen type 1 (Collagen 1) showed 
that treatment with prophylactic esomeprazole reduced 
their expression levels (Additional file 1: Table S2). Fur-
thermore, there was trend towards reduced levels of sol-
uble collagen in the BALF and lung homogenates in the 
prophylactic esomeprazole group (Additional file 1: Fig-
ure S3).
Delayed treatment of the animals (i.e. starting 10 days 
after the initiation of lung injury) with esomeprazole had 
marginal benefit that is comparable to the efficacy of pir-
fenidone (Additional file 1: Figure S4). The overall score 
of inflammation and fibrosis for the therapeutic arm is 
shown in the supplemental (Additional file 1: Table S3).
Fig. 2 The effect of esomeprazole on a lung fibroblast and b alveolar epithelial cell proliferation. Cells were synchronized and then serum‑stimu‑
lated to induce proliferation in the presence of vehicle or esomeprazole (5–50 µM). Incorporation of BrdU into newly synthesized DNA was quanti‑
fied spectrophotometrically. Data is Mean ± SEM from duplicate experiments. *p < 0.05 compared to vehicle. BrdU Bromodeoxyuridine.
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Furthermore, assessment of plasma for pro-inflam-
matory markers (e.g. IL-1β) as well as markers asso-
ciated with lung remodeling (CHI3L1 and MMP7) 
or HO1 activity (bilirubin) revealed that prophylac-
tic esomeprazole suppressed the level of circulating 
IL-1β (Fig.  8a; p  =  0.579 vs vehicle) and inhibited 
the level of MMP7 (Fig.  8b; p  =  0.0435 vs vehicle). 
In addition, esomeprazole enhanced the plasma lev-
els of the lung repair-associated protein CHI3L1 
(Fig.  8c; p  =  0.0389 vs vehicle) and the cytoprotec-
tive molecule bilirubin (Fig.  8d; p  =  0.3315 vs vehi-
cle). In addition, based on our previous finding that 
PPIs inhibit DDAH enzymatic activity and block 
the degradation of the substrate and competitive 
NOS inhibitor ADMA, we evaluated the circulat-
ing levels of both ADMA and NO in the plasma of 
esomeprazole treated animals compared to controls. 
Our results indicate that PPIs inhibit DDAH activity 
in vivo resulting in elevated levels of ADMA (Fig. 8e; 
p  =  0.0036 vs vehicle) and reduced NO (Fig.  8f; 
p = 0.0054 vs vehicle).
Apoptotic death of lung cells is mitigated by esomeprazole
Excessive destruction of resident cells is in part respon-
sible for pathological remodeling of the lungs follow-
ing injury. As such, protection against the death of lung 
epithelial cells has been proposed as a therapeutic strat-
egy in IPF [38]. Accordingly, we evaluated the effect 
of esomeprazole in protecting resident lung cells from 
apoptosis induced by bleomycin injury. Interestingly, 
esomeprazole nearly abolished the apoptosis of resident 
lung cells as shown by reduced staining of TUNEL-based 
DNA fragmentation (Fig. 9, Additional file 1: Figure S5). 
Furthermore, double staining of the lung tissue for the 
pro-apoptotic marker p53 and the epithelial cell specific 
surfactant protein marker proSP-C showed that the apop-
tosis of epithelial cells is significantly reduced upon treat-
ment with esomeprazole (Additional file 1: Figure S6).
Esomeprazole differentially regulates several signaling 
pathways associated with lung inflammation and fibrosis
Here, we carried out unbiased and comprehensive inter-
rogation of signaling pathways involved in the regulation 
Fig. 3 The PPI esomeprazole regulates ionizing radiation‑induced changes in gene expression in primary lung epithelial cells cultured in 3D matrix. 
In a inhibition of the spike in the pro‑inflammatory cytokines TNF‑α, NFκB and IL‑6 is shown. b shows downregulation of the proapoptotic protein 
p53 and c shows the upregulation of the antioxidant gene HO1 by esomeprazole. Data is Mean ± SEM from duplicate experiments. *p < 0.05 
compared to vehicle.
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of lung inflammation and fibrosis and how these path-
ways are affected by esomeprazole. We conducted 
GeneChip array of lung tissue homogenates using a bio-
analyzer as described above. Intriguingly, cluster analysis 
of the rat exon revealed that several signaling pathways 
that are known to be involved in inflammation and fibro-
sis including members of the Collagen family (such as 
Col1α2, Col3α1, Col16α1), fibronectin (FN1) and MMPs 
(MMP12) are regulated by esomeprazole. Interestingly, 
the cluster analysis of over 700 significantly regulated 
genes (by twofold or more at p  <  0.05) indicates that 
prophylactic regimen of esomeprazole treatment closely 
resembled the gene expression signature of the uninjured 
sham controls (Fig.  10). Meanwhile, we also identified 
novel transcripts that are differentially regulated by the 
PPI (Additional file 1: Figure S7). One of the genes that is 
significantly downregulated by PPI treatment was grem-
lin 1 (GREM 1). Recent studies indicate that GREM1 is 
an endogenous inhibitor of Bone Morphogenetic Pro-
teins (BMPs; BMP-2, BMP-4 and BMP-7) and is highly 
upregulated in fibrotic diseases including in IPF [39–41].
The use of PPIs is associated with prolonged 
transplant‑free survival in IPF
In two independent retrospective analyses of the Stan-
ford and UAB ILD databases, long-term use of PPIs 
was associated with a survival benefit (data not shown). 
Subsequently, we merged the databases to increase 
our power to discriminate predictors of survival. In the 
merged cohort, there were no significant differences in 
age, body mass index (BMI), smoking history or lung 
function tests in those patients on PPIs for ≥12 months 
(n = 130) compared to the controls (n = 85). However, 
the use of PPIs was associated with a significant reduc-
tion in the number of patients with lung transplantation 
or death (p = 0.025) and a 1.4 year increase in longevity 
(p < 0.001) (Table 3; Fig. 11a). We also observed a simi-
lar decrease in events of lung transplantation or death 
and increased survival time in a subgroup of patients 
who had no GER-related symptoms at their initial visit 
but were placed on PPI therapy due to anecdotal reports 
of the potential benefit of PPI use in IPF (Additional 
file  1: Table S4; Fig.  11b). Kaplan–Meier survival plots 
Fig. 4 Esomeprazole regulates bleomycin‑induced changes in gene expression in various lung cell types. In a–c suppression of pro‑inflammatory/
pro‑fibrotic markers in primary epithelial (a), endothelial (b) and fibroblasts (c) is shown. d–f demonstrates increased expression of the cytoprotec‑
tive enzyme HO1 by esomeprazole in each of these cell types. g shows upregulation of the lung repair associated gene chitinase‑3‑like 1 (CHI3L1) 
in primary lung epithelial cells. Data is Mean ± SEM from duplicate experiments. *p < 0.05 compared to vehicle.
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demonstrated improved 5-year transplant-free survival 
in PPI-treated patients (Fig.  11). Our unadjusted and 
adjusted Cox regression analyses revealed that PPI treat-
ment is an independent factor affecting transplant-free 
survival in IPF patients. Baseline forced vital capacity 
(FVC) (% predicted) (HR = 0.975, p < 0.001) and surgical 
lung biopsy (HR = 0.294, p < 0.001) were also independ-
ent factors affecting transplant-free survival (Additional 
file  1: Tables S5, S6). However, there was no significant 
difference between the PPI-treated group and the control 
group on the rate of change in FVC or diffusing capac-
ity of the lungs for carbon monoxide (DLCO), in the 
12 months following the initial pulmonary function tests 
(PFTs).
Discussion
Esomeprazole enhances the expression and activity of HO1 
in vitro and in vivo
Several studies have demonstrated multiple functions 
of the proton pump inhibitors that extend beyond sup-
pression of gastric acidity [12–14, 42–44]. For example, 
Becker et al. [14] reported that the PPIs omeprazole and 
lansoprazole possess anti-oxidant property as a result of 
induction of heme oxygenase 1 (HO1) expression and 
activity in gastric epithelial and endothelial cell lines. A 
subsequent mechanistic study demonstrated that lan-
soprazole induced HO1 expression by increasing the 
phosphorylation of the extracellular-signal related kinase 
(ERK) and Nuclear Factor-E2-related factor-2 (Nrf2) 
as well as inducing the nuclear translocation of Nrf2 
[45]. Consistently, our study shows that esomeprazole 
enhances the gene and protein expression of HO1 in vari-
ous primary lung cell types including bronchial/alveo-
lar epithelial and endothelial cells exposed to bleomycin 
injury as well as in fibroblasts isolated from the lungs of 
IPF patients. In addition, we found that esomeprazole 
substantially upregulated the expression of HO1 in lung 
epithelial cells exposed to clinically relevant dosimeter of 
ionizing radiation suggesting cytoprotection regardless 
of the stimuli. Furthermore, our in vivo study shows that 
esomeprazole induces the expression of HO1 in the lung 
tissue of animals exposed to bleomycin injury. As a result, 
the levels of bilirubin, an effector molecule for HO1, was 
enhanced in the plasma of these animals (Fig. 8). Preclini-
cal studies have shown that administration of exogenous 
bilirubin is protective from bleomycin-induced lung 
fibrosis [46].
The HO1 pathway is involved in the regulation of lung 
fibrosis
As a rate limiting enzyme in the detoxification of the 
pro-oxidant molecule heme into equimolar concentra-
tion of three essential products, HO1 enzymatic activ-
ity is critically important for physiological regulation of 
cellular and tissue heme concentration [47]. As a result, 
overexpression of HO1 has diverse beneficial effects in 
various Organ Systems including the respiratory Sys-
tem [48]. By contrast, the expression of HO1 is reported 
to be decreased in alveolar macrophages derived from 
bronchoalveolar lavage (BAL) of IPF patients [49] and in 
areas of active fibrosis (i.e. fibrotic foci) [50] suggesting 
impaired salutary effect of HO1 in IPF. Remarkably, gene 
transfer-based HO1 overexpression in preclinical settings 
was shown to mitigate pulmonary fibrosis by suppress-
ing aberrant lung remodeling and reducing apoptotic cell 
death signaling [51]. Intriguingly, our study demonstrates 
that comparable level of HO1 overexpression can be 
achieved in lung cells treated with esomeprazole (Figs. 3c, 
4d–f) suggesting the therapeutic potential of the PPIs in 
diseases where HO1 overexpression has shown promise 
(outlined in Table 1 of ref [48]). Biologically, the benefi-
cial effect associated with HO1 overexpression might be 
due to the enhanced release of the by-products of heme 
catabolism by HO1. The three effector molecules that are 
generated from the catalytic heme breakdown, ferrous 
iron (Fe2+), biliverdin and carbon monoxide (CO), are 
known to play extensive role in conferring cytoprotec-
tion. The release of Fe2+ stimulates synthesis of ferritin, 
which serves as an anti-oxidant molecule by sequestering 
free iron and slowing down iron-dependent redox (Fen-
ton) reaction [52]. Biliverdin is reduced to free bilirubin; 
an anti-oxidant and cytoprotective molecule [53, 54]. 
*
TGF-β1             - + + + + +
Vehicle - +       - - - -
Esomep - - 20 50 100           -
A83-01 - - - - - 20     
Fig. 5 The effect of esomeprazole on soluble collagen production. 
Lung Fibroblasts were isolated from patients diagnosed with IPF 
according to International Standards. Cells were treated with vehicle, 
PPI (20 to 100 µM esomeprazole) or TGF‑β1 inhibitor (A83‑01) for 
24 h. Acid soluble collagen was measured using Sircol assay. Data 
is Mean ± SEM from duplicate experiments. *p < 0.05 compared to 
vehicle.
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CO, when exogenously administered, has been shown 
to possess multiple function including anti-oxidant, 
anti-apoptotic, anti-inflammatory, anti-proliferative and 
bronchodilator activities [52, 55]. In the lungs, transient 
exposure to low dose of CO (below 500 ppm) has been 
demonstrated to be protective from inflammation and 
fibrosis in the settings of acute lung injury. Zhou et  al. 
[56] reported that inhaled CO markedly reduced the lung 
deposition of extracellular matrix (ECM) by ameliorating 
the levels of collagen I and fibronectin in a mouse model 
of IPF-like lung injury. Clinically, there is an ongoing 
Phase II interventional study evaluating the efficacy of 
inhaled CO in IPF disease progression [57].
Esomeprazole is anti‑proliferative and anti‑apoptotic
Uncontrolled proliferation of lung fibroblasts has been 
reported to contribute to the excessive ECM deposition 
that is typically seen in the lungs of IPF patients includ-
ing in areas of fibrotic foci [35]. In addition, repetitive 
injury and apoptosis of alveolar epithelial cells is associ-
ated with pathological regeneration of alveolar structure 
and leads to IPF disease progression [58]. Although the 
precise mechanism by which the epithelial cells in IPF 
lungs suffer excessive destruction is not clear, mechanis-
tic studies have demonstrated that there is differential 
upregulation of the pro-apoptotic protein p53 [59] and 
might be responsible in driving the apoptotic response in 
these cells. Interestingly, earlier studies have shown that 
PPIs inhibit the expression of proliferation markers in 
cancer cells through regulation of IL-6/STAT3 pathway 
[60]. Our proliferation study in primary lung fibroblasts 
and epithelial cells cultured in the presence or absence 
of PPI show that esomeprazole has strong and dose 
dependent anti-proliferative effect (Fig.  2) suggesting 
Vehicle Esomeprazole
Bleomycin - +          +
Vehicle - +          -
Esomeprazole - - +
*
Fig. 6 Histology of H&E stained lung sections showing suppression of inflammation by esomeprazole. Lung inflammation was induced by injuring 
animals with bleomycin instillation. The animals were treated with vehicle or low dose esomeprazole (prophylactic) for up to 28 days. Subsequently, 
lung tissues were harvested and stained with H&E to assess overall lung morphology and inflammation. Lower panel shows average lung inflamma‑
tion score of 10 animals per group. No bleomycin sham group was included as control. *p < 0.05 compared to vehicle. Representative images are 
shown.
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the potential regulation of fibroblast-driven ECM depo-
sition and epithelial-to-mesenchymal transition (EMT) 
that may result from over-proliferation of epithelial cells 
to supply precursor cells to become ECM-producing 
(myo)fibroblasts. Several findings including lineage trac-
ing studies, although inconclusive, indicate that EMT 
occurs in IPF lungs [61, 62]. Meanwhile, our preclinical 
study shows that esomeprazole has robust anti-apoptotic 
effect as demonstrated by reduced DNA fragmentation 
(Fig.  9) and p53 immunostaining (Additional file  1: Fig-
ure S6) in the lungs of animals treated with the PPI. The 
IPF literature indicates that endoplasmic reticulum (ER) 
stress is a contributing factor to increased apoptosis of 
epithelial cells and its regulation has been proposed as 
esomeprazoleVehicle
Bleomycin - +          +          
Vehicle - +          -
Esomeprazole - - +           
*
Fig. 7 Sirius Red (collagen) stained lung sections showing the degree of accumulation of collagen fibers in lung tissue. Pulmonary fibrosis was 
induced by intra‑tracheal instillation of bleomycin sulfate. The animals were treated with vehicle or low dose esomeprazole (prophylactic) for up to 
28 days prior to harvesting and staining for collagen. Treatment with esomeprazole effectively prevented the accumulation of collagen compared 
to vehicle treatment as shown. Lower panel shows average lung fibrosis score of 10 animals per group. No bleomycin sham group was included as 
control. *p < 0.05 compared to vehicle. Representative images are shown.
Table 2 Overall lung inflammation and fibrosis score in an animal model of bleomycin-induced lung injury
Animals were prophylactically treated with two doses of esomeprazole (30 or 300 mg/kg/day) or vehicle for up to 28 days. Subsequently, the lung tissues were 
harvested, stained and scored for inflammation and fibrosis.








No. of animals examined 6 10 14 15
No. of without lung lesions 6 0 5 3
Chronic inflammation (average score) 0.0 2.2 1.4 1.6
Fibrosis (average score) 0.0 2.9 1.6 1.6
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a therapeutic strategy [63]. The inhibition of apoptotic 
signaling by esomeprazole may be important in reduc-
ing destruction of the resident lung cells and may allow 
physiological regeneration of the lung tissue exposed to 
stressful stimuli as in thoracic irradiation procedures. 
Although it is not clear how esomeprazole confers pro-
tection from programmed cell death in the lung, the 
downregulation of p53 and upregulation of HO1 might 
be responsible, at least in part, for this effect. For exam-
























Fig. 8 ELISA‑based determination of plasma markers involved in lung pathobiology. a suppression of the pro‑inflammatory marker IL‑1β by 
esomeprazole; b inhibition of circulating MMP7 by esomeprazole; c increased level of the lung repair‑associated protein CHI3L1 by esomeprazole; 
d higher levels of the cytoprotective and effector molecule for HO1, bilirubin, by esomeprazole treatment; e increased circulating level of ADMA 
and f reduced plasma NO upon esomeprazole treatment. *p < 0.05 compared to vehicle. IL-1β interleukin 1 beta, MMP7 matrix metalloproteinase‑7, 
CHI3L1 chitinase 3‑like 1, HO1 heme oxygenase‑1, ADMA asymmetric dimethylarginine, NO nitric oxide.
Vehicle PPI
Fig. 9 TUNEL‑stained lung tissue sections showing inhibition of DNA fragmentation (shown in red) by the PPI esomeprazole. Animals injured by 
bleomycin instillation were treated with vehicle or esomeprazole (prophylactic) prior to sacrifice and staining for DNA fragmentation. Representa‑
tive images are shown. The nuclei are stained with DAPI. DAPI 4′,6‑Diamidino‑2‑Phenylindole.
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[47]. Furthermore, HO1 induction might be responsible 
for the anti-proliferative effect of esomeprazole. Low 
concentration of CO has strong anti-proliferative effect 
and has been reported to regulate the proliferation of 
airway smooth muscle cells in part due to inhibition of 
ERK/MAPK signaling [64].
Esomeprazole possesses anti‑fibrotic activity in vitro, 
ex vivo and in vivo
Our cell culture study of normal lung fibroblasts exposed 
to bleomycin injury in the presence or absence of esome-
prazole demonstrates that the gene expression of a num-
ber of pro-fibrotic markers including collagen type I and 
Fig. 10 Hierarchical clustering of over 700 genes that are significantly regulated during the process of lung inflammation and fibrosis. Total RNA 
was extracted from the lungs of bleomycin‑injured animals that received vehicle or esomeprazole (prophylactic or therapeutic course) treatment. 
Subsequent Genechip microarray analysis of the rat exon revealed that several transcripts are differentially regulated by esomeprazole and the 
prophylactic esomeprazole treatment group closely clustered with uninjured sham group. S sham, P prophylactic esomeprazole, V vehicle, T thera‑
peutic esomeprazole.
Table 3 Baseline demographics of  patient population and  comparison of  pulmonary function tests (PFTs), lung trans-
plantation or death, and transplant-free survival time between PPI treatment group and control group
Data are presented as median (25th–75th percentile) or number (percentage).
Items PPI treatment group (n = 130) Control group (n = 85) p‑value
Age (years) 66 (55–73) 67 (61–76) 0.112
Male gender 81 (62.3) 54 (63.5) 0.856
Ethnicity (white, non‑hispanic) 93 (71.5) 69 (81.2) 0.109
Surgical lung biopsy 61 (46.9) 35 (41.2) 0.407
BMI (kg/m2) 27.7 (24.5–32.5) 27.8 (25.4–30.8) 0.945
Smoking history (pack years) 6 (0–25) 5 (0–30) 0.850
Pulmonary hypertension 22 (16.9) 19 (22.4) 0.333
Lung function test
 FVC% predicted 65 (54–75) 62 (51–77) 0.440
 DLCO% predicted 52 (42–65) 47 (36–57) 0.064
Patients with lung transplantation or death 77 (59.2) 63 (74.1) 0.025
Transplant‑free survival (years) 3.4 (1.8–5.3) 2.0 (1.2–4.1) 0.001
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fibronectin as well as matrix metalloproteinases (MMPs) 
including MMP7 (matrilysin) is downregulated (Fig. 4c). 
In addition, our ex vivo study shows that fibroblasts iso-
lated from the lungs of IPF patients release less soluble 
collagen in response to TGFβ stimulation when incu-
bated with esomeprazole compared to vehicle control 
(Fig.  5). Furthermore, our biochemical assays of soluble 
collagen and hydroxyproline indicate that there is trend 
towards reduced collagen deposition in the BAL and 
lung tissue of bleomycin-challenged animals treated with 
esomeprazole (Additional file 1: Figure S3). Intriguingly, 
Sirius Red stained lung histology of animals challenged 
with bleomycin show remarkable inhibition of fibrosis by 
prophylactic esomeprazole (Fig. 7). In addition, adminis-
tration of esomeprazole in a therapeutic regimen (start-
ing day 10 post bleomycin challenge) shows marginal yet 
similar degree of reduction in fibrosis to that of pirfeni-
done treatment (Additional file 1: Figure S5; Table S3). It 
is interesting to note that IPF patients on anti-acid ther-
apy (where the majority were on PPIs) showed reduced 
baseline fibrosis score compared to patients not taking 
the medication [8].
Esomeprazole attenuates inflammation in primary lung 
cells and in vivo
The anti-inflammatory effect of PPIs has long been 
appreciated and their potential utility for inflamma-
tory conditions has been discussed [13]. Although the 
anti-inflammatory effect of the drug has been proposed 
to be independent of gastric acid suppression, the exact 
mechanism is not clear. However, downregulation of 
the expression of several key mediators of inflamma-
tion including VCAM-1, TNFα, IL-1β and NFκB as well 
as decreased adherence of inflammatory cells to vascu-
lar wall have been reported [12, 20, 21, 65]. In the pre-
sent study, we demonstrated that esomeprazole strongly 
diminished bleomycin- and ionizing radiation- induced 
elaboration of several pro-inflammatory cytokines 
(Figs. 3, 4). In addition, we found that the level of IL-1β 
in the plasma of animals subjected to bleomycin-induced 
lung injury was attenuated upon treatment with esome-
prazole (Fig.  8). Remarkably, H&E stains of lungs from 
bleomycin-injured animals that received prophylactic 
esomeprazole treatment displayed minimal inflamma-
tion with about a third of the animals in this group show-
ing virtually no inflammation suggesting that PPIs have 
potent anti-inflammatory property in  vivo and may be 
therapeutically useful in extra-intestinal inflammatory 
diseases.
Esomeprazole regulates the iNOS‑DDAH pathway
About a decade ago, Genovese and colleagues [26] dem-
onstrated that genetic or pharmacological suppres-
sion of inducible NOS (iNOS) reduces lung fibrosis in 
mice exposed to bleomycin injury. Recently, Pullamsetti 
et  al. [24] confirmed the pathological role of iNOS in 
Fig. 11 Kaplan‑Meier 5‑year survival plot of IPF patients. In a data from all 215 IPF patients is shown; In b only data from patients without history of 
gastroesophageal reflux (GER) symptoms (n = 102) is shown.
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lung fibrosis and extended the finding by revealing co-
localization of iNOS with DDAH in explanted lungs of 
IPF patients suggesting the interdependence of the two 
enzymes in the disease process. Interestingly, the pro-
inflammatory/pro-fibrotic cytokine IL-1β upregulates 
the expression of both iNOS and DDAH [66] and a coop-
erative interaction between DDAH and TGFβ has been 
proposed [24, 67]. These interactions suggest that there 
may be cross-talk among inflammatory and pro-fibrotic 
cytokines and the iNOS/DDAH pathway. Strikingly, the 
work of Pullamsetti et  al. revealed that the expression 
and activity of DDAH was increased in IPF patient lungs 
and pharmacological inhibition of DDAH was effective in 
restoring lung compliance in bleomycin-challenged mice 
[24]. Interestingly, we have discovered that PPIs as a class 
are effective inhibitors of human DDAH activity and 
esomeprazole is among the most potent PPIs in regulat-
ing DDAH [22] suggesting that the observed anti-fibrotic 
activity of esomeprazole in our preclinical study may in 
part be due to regulation of the iNOS-DDAH pathway.
A number of studies have shown that iNOS is induced 
in the setting of airway inflammation and injury [68, 69]. 
In IPF, gastric refluxate or other injurious stimuli are 
expected to release pro-inflammatory cytokines [70] that 
may provoke induction of iNOS. Indeed, clinical studies 
revealed that NO levels are elevated in BAL and lung tis-
sue of patients with IPF [25, 71], and iNOS expression is 
upregulated by about threefold in explanted lungs from 
these patients [24]. Unlike endothelial NOS (eNOS), 
iNOS generates superoxide anion as well as NO which 
combine to produce the highly reactive peroxynitrite 
anion (OONO−). OONO− forms nitrotyrosine adducts 
in the tissue, which interfere with normal cell signaling 
including proliferation and survival [72]. In addition, the 
nitrosative stress activates NFκB and other oxidant-sen-
sitive transcriptional pathways to increase the expression 
of chemokines and adhesion molecules that augment the 
inflammatory response. Indeed, our data showing that 
the iNOS/DDAH pathway is regulated by esomeprazole 
is intriguing.
Effect of PPIs on measures of lung function and survival 
in IPF patients
The relationship between gastroesophageal reflux (GER; 
an indication for which the PPIs are primarily pre-
scribed) and lung fibrosis is well appreciated [73–76]. 
Studies utilizing esophageal pH monitoring have docu-
mented abnormal pH readings in the distal and proximal 
esophagus of a large proportion of IPF patients [10, 77, 
78]. However, the precise association between GER and 
IPF is unclear. There are two major hypotheses regard-
ing this relationship. The first hypothesis involves GER 
as a sequel of IPF. Decreased lung compliance in patients 
with IPF may lead to increased swings in pleural pressure 
causing dysfunction of the lower esophageal sphincter 
and eventually leading to GER [10, 79]. The alternative 
hypothesis revolves around chronic microaspiration of 
small gastric droplets either triggering acute exacerba-
tions or leading to progressive injury and fibrosis [10, 
80]. However, discordance between the high prevalence 
of GER (200 per 1,000) and the orphan classification of 
IPF (300 per 1,000,000) [81, 82], lack of clear evidence 
demonstrating a causal role of microaspiration in clinical 
pulmonary fibrosis, the grossly distinct histopathological 
outcomes between acid-induced lung injury in animals 
(mainly granulomatous inflammation) and clinical IPF 
(honeycomb changes without or minimal inflammation) 
and anatomical differences in the sites of fibrosis are find-
ings that pose questions about a causal relationship [83, 
84].
It has been assumed that the presumed benefit of PPIs 
in measures of lung function in IPF is due to a reduc-
tion in gastric acidity that would reduce potential lung 
injury due to microaspiration. Although GER commonly 
accompanies IPF [10, 76, 85]; and it is believed that anti-
reflux strategies may benefit IPF [70], several reports 
have indicated the lack of direct and complete association 
between the progression of GER and IPF [10, 77, 80, 86–
88]. Paradoxically, some IPF patients who undergo fun-
doplication therapy have been initially placed on PPIs and 
failed to suppress symptoms of reflux such as heartburn 
and regurgitation despite the PPIs; making them eligible 
for the surgical procedure (see the question and answer 
section of ref [70]). Thus, the use of PPIs may not pro-
vide for effective reflux control [70] and gastric reflux and 
microaspiration may still persist in IPF patients placed 
on PPIs [8, 10, 79, 89]. Furthermore, there is no evidence 
that the PPI-induced changes in gastric pH would reduce 
(lung) tissue injury in the event of microaspiration.
In light of our in  vitro findings, we chose to focus 
our analysis of interstitial lung disease (ILD) database 
on the use of PPIs and potential survival benefit of IPF 
patients. Intriguingly, we found that the use of PPIs for 
12  months or longer was associated with significantly 
longer transplant-free survival compared to IPF patients 
who did not take PPIs (Fig. 11). In principle, our finding 
that the use of PPIs is associated with favorable outcome 
in IPF is similar to what has been previously reported 
in the literature. Two retrospective studies have sug-
gested an association between PPI use and improved 
survival [7, 8]. Moreover, deterioration in lung function 
has been correlated with poor adherence to PPI therapy 
[7]. In a case series of 4 IPF patients, Raghu et  al. [7] 
observed clinical improvement in IPF patients on PPI 
therapy. Recently, Lee and colleagues [8] conducted 
a retrospective analysis of 204 IPF patients from two 
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ILD databases. Ninety-eight (98) of their patients were 
on some form of pharmacological anti-reflux therapy 
as follows: PPIs = 84, H2-blockers = 12 and combined 
PPI and H2-blocker  =  2. The use of anti-reflux medi-
cations (composed of 87% of patients taking PPIs) was 
associated with longer survival. In our study, we also 
observed survival benefit including in patients that did 
not have any history of GER or GER-related symptoms 
(Fig. 11b; Additional file 1: Table S4). In light of this, it 
is interesting to note that esomeprazole regulated the 
gene expression and plasma levels of MMP7 (Figs. 4, 8b) 
since clinical studies have shown that elevated level of 
MMP7 (Matrilysin) is associated with increased lung 
fibrosis and independently predicts survival in IPF [90, 
91]. Meanwhile, the reduced baseline radiologic fibro-
sis noted by Lee et al. [8] suggest that PPIs may possess 
an anti-fibrotic effect, given our present in  vitro and 
preclinical findings, however, the retrospective nature 
of the clinical data does not allow such a firm conclu-
sion. Furthermore, a recent analysis of IPF patients who 
participated in clinical trials and were prospectively 
followed by the IPF clinical research network (IPFnet) 
showed a slower rate of forced vital capacity (FVC) 
decline in IPF patients on anti-reflux therapy (of whom 
over 90% were on PPIs) [9]. Surprisingly, the use of 
anti-reflux therapy was also associated with fewer epi-
sodes of acute exacerbations compared to IPF patients 
who did not take these medications [9]. Intriguingly, we 
discovered that esomeprazole significantly upregulated 
the expression and rat plasma levels of chitinase 3-like 
1 (CHI3L1) protein (Fig.  8). A recent study reported 
that the lung expression and plasma levels of endog-
enous CHI3L1 is reduced in IPF patients with episodes 
of acute exacerbation compared to IPF patients in a sta-
ble condition [92]. Therefore, if our data is translated to 
humans, induction of CHI3L1 by PPIs might have been 
responsible, at least in part, for the reported incidences 
of fewer acute exacerbations associated with the use of 
PPIs in patients with respiratory diseases including IPF 
[9] and chronic obstructive pulmonary disease (COPD) 
[43].
Conclusions
A number of inflammatory cytokines including TNFα 
and IL-1β are overexpressed in preclinical models of 
lung fibrosis and in lung tissue from IPF patients. This 
overexpression is known to sustain TGFβ expression 
and to promote the progression of the disease [93, 94]. 
By contrast, inhibition of these cytokines has favorable 
effects on fibrotic processes in cell culture and in ani-
mal models of lung injury. The literature and our pre-
sent study demonstrate that the PPIs dose-dependently 
inhibit a number of pro-inflammatory/pro-fibrotic 
cytokines. We showed that a classic PPI (esomeprazole) 
regulated a number of players involved in the pathogen-
esis of lung injury including the iNOS/DDAH pathway. 
The inhibition of NOS/DDAH by the PPIs is impor-
tant since increased NOS activity is known to reduce 
the tone of the esophageal sphincter [95]. Increased 
DDAH activity in the sphincter would be expected to 
enhance NO production, with resultant relaxation of the 
sphincter, promoting reflux. We propose, therefore, that 
PPIs may exhibit pleiotropic effect in mitigating lung 
injury and fibrosis in IPF through presumed suppres-
sion of acid reflux and inhibition of excessive release of 
cytokines while promoting salutary effect of HO1 and 
its bioactive effector molecules. Intriguingly, our retro-
spective analysis of ILD databases indicate that PPI use 
is associated with increased longevity in IPF patients. 
Our preclinical work suggests that there is a plausible 
biological mechanism for the potential therapeutic ben-
efit associated with the use of PPIs in IPF. It is intrigu-
ing to note that the PPI esomeprazole suppressed lung 
inflammation and fibrosis in species (i.e. rats) that do not 
naturally display GER [96]. This finding suggests that the 
mechanism predominantly responsible for the therapeu-
tic effect of the PPIs in pulmonary fibrosis is less likely 
to be suppression of GER. This finding provokes the 
temptation to speculate that PPIs might be beneficial in 
IPF regardless of the patients’ GER status. However, this 
possibility needs to be evaluated in prospective clinical 
studies by placing IPF patients with or without GER on 
PPIs and objectively studying measures of lung func-
tion. Moreover, future studies need to determine the 
concentration of PPI that is achievable in the lungs from 
standard oral dosing. A proportion of our present study 
seems to indicate that the PPI concentration necessary 
to achieve optimal effect on markers of inflammation/
fibrosis (about 50  µM) is higher than the plasma con-
centration attained from a standard oral dosing for GER 
(up to 14 µM) [97, 98]. However, the medical records of 
many of our IPF patients included in the analysis indi-
cate that many have been chronically dosed 2–3 times 
higher than the standard oral dose in an attempt to con-
trol GER symptoms (heartburn, regurgitation, nausea 
and chest pain). This higher dosing and chronic treat-
ment of our IPF patients for several months to years 
may have provided beneficial effect similar to what we 
observed in our cell biological and preclinical studies. 
Furthermore, there may be discordance between plasma 
and tissue levels of PPIs. Interestingly, some studies pro-
pose that PPIs can accumulate in some tissues to milli-
molar levels [13, 42]. Finally, future mechanistic studies 
are warranted to investigate the precise mechanism by 
which PPIs regulate lung injury. In addition, prospec-
tive and controlled clinical trials are necessary to define 
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the role of PPIs as potential therapeutic agents for IPF as 
well as address the contribution of GER in the pathogen-
esis of IPF.
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